Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

Open Heart

Study or Subgroup	Sacubitril/valsartan Events	Total	Control Events	Total	Weight	Risk Ratio M-H, Fixed, 95% CI	Risk Ratio M-H, Fixed, 95% CI
6.2.1 Enalapril							
Li J 2019 (1)	17	62	29	64	3.8%	0.61 [0.37, 0.98]	
PARADIGM-HF 2014	537	4187	658	4212	87.1%	0.82 [0.74, 0.91]	
PIONEER-HF 2018	35	440	61	441	8.1%	0.58 [0.39, 0.85]	
Subtotal (95% CI)		**4689**		**4717**	**98.9%**	**0.79 [0.72, 0.88]**	
Total events	589		748				
Heterogeneity: Chi² = 4.16, df = 2 (P = 0.13); I² = 52%							
Test for overall effect: Z = 4.56 (P < 0.00001)							
6.2.2 Valsartan							
Fan TT 2019	5	35	8	35	1.1%	0.63 [0.23, 1.72]	
Subtotal (95% CI)		**35**		**35**	**1.1%**	**0.63 [0.23, 1.72]**	
Total events	5		8				
Heterogeneity: Not applicable							
Test for overall effect: Z = 0.91 (P = 0.36)							
Total (95% CI)		**4724**		**4752**	**100.0%**	**0.79 [0.72, 0.87]**	
Total events	594		756				
Heterogeneity: Chi² = 4.36, df = 3 (P = 0.22); I² = 31%							
Test for overall effect: Z = 4.63 (P < 0.00001)							
Test for subgroup differences: Chi² = 0.21, df = 1 (P = 0.65), I² = 0%							

Forest plot x-axis: 0.2 — 0.5 — 1 — 2 — 5; Sacubitril/valsartan   Control